Chardan Capital Weighs in on Prime Medicine FY2026 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Research analysts at Chardan Capital issued their FY2026 earnings per share estimates for Prime Medicine in a research report issued on Monday, November 10th. Chardan Capital analyst G. Livshits expects that the company will post earnings of ($0.80) per share for the year. Chardan Capital currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share.

Several other analysts have also recently issued reports on the company. Citigroup decreased their price objective on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a report on Tuesday. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Prime Medicine in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $9.21.

Prime Medicine Trading Down 6.2%

Shares of Prime Medicine stock opened at $3.33 on Wednesday. The firm has a market cap of $448.13 million, a PE ratio of -1.62 and a beta of 2.64. The stock has a 50 day moving average of $4.99 and a 200 day moving average of $3.50. Prime Medicine has a 12 month low of $1.11 and a 12 month high of $6.94.

Hedge Funds Weigh In On Prime Medicine

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Alphabet Inc. raised its holdings in Prime Medicine by 10.0% during the 3rd quarter. Alphabet Inc. now owns 16,562,498 shares of the company’s stock valued at $91,756,000 after buying an additional 1,500,000 shares during the period. ARK Investment Management LLC boosted its stake in Prime Medicine by 135.8% during the third quarter. ARK Investment Management LLC now owns 5,477,851 shares of the company’s stock worth $30,347,000 after buying an additional 3,155,182 shares during the period. Vanguard Group Inc. increased its position in Prime Medicine by 35.7% during the third quarter. Vanguard Group Inc. now owns 4,921,865 shares of the company’s stock valued at $27,267,000 after acquiring an additional 1,294,355 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Prime Medicine by 4.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,143,096 shares of the company’s stock valued at $8,245,000 after acquiring an additional 165,268 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Prime Medicine by 127.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,629,924 shares of the company’s stock valued at $20,110,000 after acquiring an additional 2,035,406 shares during the period. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.